PCSK9 and cancer: Two mAbs that neutralize PCSK9, Evolocumab and Alirocumab, have garnered approval from EMA and the US FDA for the clinical intervention of refractory hyperlipidemia, thereby paving the way for utilizing PCSK9 as a target in cancer therapy.